JP2016516076A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516076A5
JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
insulin
chain
long
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP6755175B2 (ja
JP2016516076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055533 external-priority patent/WO2014147141A1/en
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Active JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194.0 2013-03-20
EP13160194 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 true JP2016516076A5 (enExample) 2017-04-27
JP6755175B2 JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Active JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (enExample)
EP (1) EP2976096B1 (enExample)
JP (1) JP6755175B2 (enExample)
CN (1) CN105188736A (enExample)
WO (1) WO2014147141A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2018096163A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
CN110022935A (zh) 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
MY204354A (en) 2017-02-01 2024-08-24 Novo Nordisk As Procoagulant antibodies
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3815106B1 (en) * 2018-06-26 2024-12-25 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1829738B (zh) * 2003-08-05 2012-07-04 诺沃挪第克公司 新型胰岛素衍生物
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
PL1969004T3 (pl) * 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US8962794B2 (en) * 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2011252127B2 (en) * 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RS59423B1 (sr) * 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
MX342922B (es) * 2011-02-01 2016-10-19 Novo Nordisk As Purificacion de insulina.
AU2012223282B2 (en) * 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2844274B1 (en) * 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime

Similar Documents

Publication Publication Date Title
JP2016516076A5 (enExample)
DK1965823T3 (en) Methods of administering hypoglycemics
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
US20100087365A1 (en) Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
JP2007523881A5 (enExample)
RU2012123739A (ru) Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
JP2014520798A5 (enExample)
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
JP2014501762A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2011241213A5 (enExample)
JP2011001381A (ja) Glp−1医薬組成物
JP2014520798A (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
JP2013526501A5 (enExample)
Brandt et al. Are peptide conjugates the golden therapy against obesity?
US20040037826A1 (en) Combined use of a modulator of CD3 and a GLP-1 compound
JP2015517458A5 (enExample)
RU2014147674A (ru) Фармацевтическая композиция
CN110013542B (zh) 一种预防/治疗突触核蛋白病的药物及多肽类似物
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
JP2014500244A5 (enExample)
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
Shibata et al. Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch